2114. Evaluation of Isavuconazole Activity against Non-fumigatus Aspergillus and cryptic Aspergillus species Causing Invasive Infections Worldwide

BACKGROUND: Isavuconazole (ISC) is considered first-line therapy for the treatment of invasive aspergillosis (IA). There is limited data on antifungal susceptibility testing of clinically relevant non-fumigatus (non-AFM) and cryptic species of Aspergillus (cryAsp) causing IA. The activity of ISC and...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G, Rhomberg, Paul, Kantro, Valerie, Hatch, Beth, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676911/
http://dx.doi.org/10.1093/ofid/ofad500.1737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676911/
http://dx.doi.org/10.1093/ofid/ofad500.1737

Ejemplares similares